论文部分内容阅读
目的了解深圳市结核分枝杆菌耐药情况,为深圳市结核病控制提供科学依据。方法依据(WHO/IUALD)结核病耐药指南,将深圳市1999—2008年间所有新涂阳和新登记的复治涂阳的肺结核作为监测对象,对6702例成功分离的结核分枝杆菌菌株,用比例法进行药物敏感实验。结果总耐药率37.8%,初始耐药率22.1%,获得性耐药率37.8%;耐多药率4.7%,初始和获得性耐多药率分别为3.8%和16.3%;初治和复治患者的耐单药率和单药耐药频率均以S和H为主,复治组R的耐单药率显著高于初治组;初治患者含耐R的病例共333例,其中耐HR211例,占60%;复治患者含R耐药的患者共99例,其中耐HR78例,占79%。结论深圳市耐药结核病的发生率较高,耐药现状应该引起高度重视。
Objective To understand the drug resistance of Mycobacterium tuberculosis in Shenzhen and provide a scientific basis for the control of tuberculosis in Shenzhen. Methods According to the WHO / IUALD guidelines for tuberculosis drug resistance, all newly smeared and newly registered smear-positive pulmonary tuberculosis from 1999 to 2008 in Shenzhen were used as monitoring targets. 6702 cases of Mycobacterium tuberculosis isolates successfully isolated were treated with Proportional method for drug-sensitive experiments. Results The total drug resistance rate was 37.8%, the initial drug resistance rate was 22.1%, the acquired drug resistance rate was 37.8%, the multidrug resistance rate was 4.7%, and the initial and acquired multidrug resistance rates were 3.8% and 16.3% respectively. Treatment-resistant patients with single drug resistance and single drug resistance frequency are S and H-based retreatment R group was significantly higher than the monotherapy drug-naive group; initial treatment of patients with R-resistant cases a total of 333 cases, of which Resistant to HR211 cases, accounting for 60%; Retreatment patients with R resistance in a total of 99 patients, of which resistance to HR78 cases, accounting for 79%. Conclusion The incidence of drug-resistant TB in Shenzhen is high and the status of drug-resistance should be given high priority.